Followed for cancer or survivorship care at one of the following institutions: \r\n* Dana Farber/Harvard Cancer Center\r\n* Hospital for Sick Children\r\n* Childrens Hospital of Eastern Ontario\r\n* Oregon Health and Science University\r\n* Seattle Childrens Hospital\r\n* Yale University
Have had cancer other than MB, NB, ES or RMS for Part A of the study or cancer other than MB in the previous  years for Parts A and B
Histopathologic evidence of cancer based upon pathologist's report.
Other active cancer
Subjects with peritoneal disease who have failed prior standard chemotherapy and have histologic confirmation of platinum-resistant or refractory epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, endometrial cancer, cervical cancer, vaginal and vulvar cancer, uterine sarcomas including leiomyosarcoma, carcinosarcoma or high grade endometrial stromal sarcoma, gastroesophageal cancer, pancreatic cancer, cholangiocarcinoma, colorectal cancer, gastrointestinal neuroendocrine tumors, or mesothelioma will be enrolled.
FAZ single agent: NSCLC/ TNBC/ Endometrial cancer / Anaplastic thyroid cancer/Selected indication(s) in dose expansion group every  Weeks (QW) dosing regimen
Inability to perform phone call and clinical follow-up at MD Anderson Cancer Center (MDACC)
Incurable cancer
History of anal cancer
Completed cancer treatment with no evidence of active cancer; all post-surgical swelling must be resolved.
Evidence of another malignancy, exclusive of a skin cancer that requires only local treatment
Primary resectable rectal cancer
Estimated time to first treatment of  years or less according to MD Anderson Cancer Center (MDACC) nomogram.
Any other cancer (excluding radically operated localized squamous skin cancer) with clinical activity within the last  years
Both male and female patients must have a pelvic tumor and are scheduled to have surgery at University of Texas (UT) Monroe Dunaway (MD) Anderson Cancer center that require hemipelvectomy, resulting in pelvic ring disruption
Other known active cancer(s) likely to require treatment in the next two () years
Prior history of invasive HPV-related anogenital cancer (cervical, vaginal, vulvar, penile, or anal cancer), or oropharyngeal cancer (base of tongue, tonsil); prior cancer at other sites (including most of oral cavity) or larynx are not exclusions
Patient who are capable to return to MD Anderson Cancer Center (MDACC) for follow-up
Consented for tissue collection on Mays Cancer Center repository -
Patients with active nd malignancies other than myelofibrosis, AML, excised skin cancer, early stage cervical and prostate cancer
Other known active cancer(s) likely to require treatment in the next two () years
FIGO grade  or  endometrioid cancer
Patients must have adequate TIL that were previously harvested and then cryopreserved on MD Anderson Cancer Center (MDACC) protocol -
Cancer antigen (CA) - level (to establish baseline)
Patients must be willing to stay within  hours drive of MD Anderson Cancer Center whilst receiving Ipilimumab therapy. Patient must also agree to present to MD Anderson emergency center while on Ipilimumab therapy.
Evidence of extra-abdominal cancer dissemination or hematogenous cancer dissemination
Patients must have adequate transoral exposure of the oral cavity and laryngopharynx for TORS instrumentation; for the non-surgical arm: Patients planned to receive non-surgical treatment (e.g., chemo and/or radiation); the  surgical (TORS) arms include: tonsil cancer: T, tonsil cancer: T, base of tongue cancer: T, base of tongue cancer: T, supraglottic cancer, unknown primary cancer, and other tumors; the  non-surgical arms are: tonsil cancer, base of tongue cancer, and supraglottic/hypopharyngeal/other cancers
Patients may be on other trials (either here at M.D. Anderson Cancer Center or at an outside institution) as long as the other eligibility criteria are met
Inclusion Criteria:\n\n        Caregivers\n\n          -  Mothers and fathers (biologic/adoptive/step parents/legal guardians) of pediatric\n             cancer survivors\n\n          -   years or older\n\n          -  Fluent in English\n\n        Pediatric Cancer Survivors\n\n          -  Diagnosis of cancer\n\n          -  between - years of age at study entry\n\n          -  off active cancer treatment for  months to  years, or in the maintenance phase of\n             treatment\n\n          -  reside with a participating caregiver\n\n          -  able to engage in PA tailored to current medical status\n\n          -  NOT taking medications that affect body weight, e.g., steroids within  months of\n             enrollment\n\n          -  at or above the th BMI %ile.\n\n        Exclusion Criteria:\n\n        Caregivers\n\n          -  are non-ambulatory\n\n          -  do not reside with the PCS at least % of the time.\n\n        Pediatric cancer survivor\n\n          -  relapse during the intervention\n\n          -  taken a medication known to affect body weight such as oral steroids or antipsychotic\n             medications within  months of enrollment
Operable cancer
Currently benefiting from the treatment with ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone, as determined by the investigator.
Patients with Primary Hepatic Cancer have not recently been treated with antivirals.
History of other cancer within  years
BLADDER: Patients must be considered to be an operative candidate by the urology service at MD Anderson Cancer Center
Patients must not have extrahepatic cancer
Patients with other active malignancies (besides AML, ALL, MDS) requiring treatment or where there is concern of progression are ineligible for this study; however, patients with previously treated skin cancer, early stage cervical or prostate cancer may be eligible if there is no evidence of residual disease
Patients with a history of cancer other than skin cancer within  years of the initiation of protocol treatment
Nonmelanomatous skin cancer.
History of other cancer within  years.
Adequate recovery from most recent systemic or local treatment for cancer
Cancer must be considered incurable by the treating clinician
No history of another active cancer
Prior surgery for cancer of the anus that removed all macroscopic anal cancer
Direct evidence of regional or distant metastases after appropriate staging studies, or synchronous primary or prior malignancy in the past  years other than nonmelanomatous skin cancer or in situ cancer
Histopathologically confirmed diagnosis of one of the following cancer types:\r\n* Salivary gland cancer without the presence of extracapsular extension and/or positive surgical margin\r\n* Skin cancer\r\n* Melanoma
Eligibility for pediatric patients will be determined in conjunction with an MD Anderson Cancer Center (MDACC) pediatrician
Prior invasive cancer (except nonmelanoma skin cancer) unless disease free for at least  years or life expectancy without treatment is greater than  years, e.g., low risk localized prostate cancer
A minimum of  patients in the trial (~%) will need to have a PIKCA mutation in their cancer
Group : Patients with ERK mutated cancer
Intention for chemotherapy administration at MD Anderson Cancer Center
Ovarian cancer, primary peritoneal, and fallopian tube participants in the Phase  and Phase -T portions of this trial must have either measurable cancer by RECIST . criteria or an elevated cancer antigen (CA) level at least twice the upper limit of normal on two separate occasions at least  day but not more than  months apart; at least one of the samples should be within  week of starting treatment; patients with both an elevated CA and measurable cancer will be followed by RECIST . criteria; patients with only an elevated CA level will be followed by modified Gynecologic Cancer Intergroup (GCIG) criteria
Patients must have either heregulin-positive cancer, cancer with RAS mutation, IGF- positive cancer, or RAS wild type cancer.
For patients with oropharyngeal cancer, p status is known or can be determined
Toxic effects of previous anti-cancer chemotherapy, experimental cancer therapy, or cancer immunotherapy have not normalized.
The patient has a history of another primary cancer, with the exception of:
No other active cancer
Survivor of childhood cancer for ? years (N = ) and no history of childhood cancer (N = )
History of another primary cancer, with the exception of:
CANCER-RELATED CRITERIA
Active second malignancy (except non-melanomatous skin cancer or incidental prostate cancer found on cystectomy): active secondary malignancy is defined as a current need for cancer therapy or a high possibility (>%) of recurrence during the study.
Patients with known evidence of active cancers, or other cancer under active treatment; exceptions include patients with no evidence of disease receiving adjuvant hormone-based therapy or either breast or prostate cancer
Baseline cancer antigen (CA)- must be >=  units/mL
Unwilling to participate in follow-up clinical appointments at MD Anderson Cancer Center (MDACC)
Other active malignancy requiring therapy; exceptions: non-melanotic skin cancer or any cancer that in the judgment of the investigator will not interfere with treatment plan and response assessment; patients with >= % of the bone marrow radiated for other diseases are not eligible
T cancer
Anyone with a previous cancer diagnosis (excluding skin cancer)
In active cancer treatment or have completed active cancer treatment within  months of obtaining consent (with the exception of adjuvant hormonal therapy)
Radiation treatment for this cancer was completed (or will be completed) at MD Anderson Cancer Center (post-RT study only)
Receiving radiation treatment for this cancer at any site within the MDACC Cancer Network (Cancer Network study only)
Breast cancer diagnosis, stage , , or  (solely for patients enrolled at Montefiore Medical Center, St. Barnabas, Jacobi Medical Center, and North Central Bronx)
Be a cancer care provider (CCP) working at one of the above cancer centers
Have direct contact with cancer patients
Primary cancer care at the Massachusetts General Hospital (MGH) Cancer Center or Dana-Farber Cancer Institute (DFCI)
Patients with advanced cancer who are receiving treatment at Dana-Farber Cancer Institute (DFCI) in the thoracic oncology group and the DFCI-affiliated St. Elizabeths Hospital
Seen at an outpatient clinic at MD Anderson Cancer Center or The Harris Health System (LBJ) Hospital General Oncology Clinic.
Cancer survivor, with no evidence of active disease
Individuals with a history of another malignancy are not eligible if the cancer is under active treatment or the cancer can be seen on radiology scans or if they are off cancer treatment but in the opinion of their oncologist have a high risk of relapse within  years
Other active cancer
No active cancer therapy (excluding chemoprevention) in the past three months, and no cancer therapy currently planned in the next  months
Cancer treatment or follow-up for lymphoma at the Massachusetts General Hospital (MGH) Cancer Center
Participation in qualitative interview during phase  (Dana-Farber Harvard Cancer Center [DF/HCC] -)
All patients undergoing RC for bladder cancer with urinary diversion at MD Anderson Cancer Center (MDACC).
Is scheduled to undergo cystoscopy with bladder resection procedure under general anesthesia requiring neuromuscular relaxation using rocuronium bromide to secure airway and requiring neuromuscular reversal at The University of Texas Monroe Dunaway (MD) Anderson Cancer Center - Mays Clinic (ambulatory care building [ACB]-outpatient)
Workshops B and C ( -  weeks - City of Hope)\r\n* Cancer patients (all types and at any time point in their disease)\r\n* Note: documentation to confirm this eligibility criteria will not be requested; self-reporting as a cancer patient will be considered adequate
Outpatient at MD Anderson Cancer Center
CAREGIVER: Spouse or cohabitating intimate partner of an advanced cancer patient being evaluated at the University of Pittsburgh Medical Center (UPMC)s Liver Cancer Center (LCC)
Active cancer
Patients who are receiving neoadjuvant chemotherapy treatment at University of Texas (UT) MD Anderson Cancer Center
Patients who are not receiving their primary cancer care and chemotherapy at MD Anderson Cancer Center
No active cancer therapy (excluding chemoprevention) in the past year, and no cancer therapy planned in the next  months
Have been scheduled for an intramedullary nailing (IM) surgery with the department of Orthopaedic Oncology at University of Texas (UT) MD Anderson Cancer Center
History of curative-intent radiotherapy at MD Anderson Cancer Center (MDACC) for a new primary H&N cancer in past  years
Patient must have either a history of cancer or active cancer
PATIENTS ONLY: Currently receiving treatment (e.g. radiotherapy, chemotherapy) at MD Anderson Cancer Center
Expected to continue cancer care at University of Wisconsin Carbone Cancer Center (UWCCC) for the duration of the study
Actively receiving care at the Duke Cancer Center, Durham Regional Hospital, or Duke Raleigh Hospital
Are undergoing treatment for pancreatic cancer at Fox Chase Cancer Center (FCCC)
Have any other active cancer
Recurrence of cancer or other active cancer
Outpatient at MD Anderson Cancer Center seen by the supportive care service, thoracic medical oncology, cancer pain clinic, or cardiopulmonary clinic
Cancer patient
No evidence of cancer (NED)
Patients at MD Anderson with a cancer history who are either undergoing active treatment or who have completed treatment for their cancer
Adolescents and young adults who have completed cancer treatment within the past three months of all cancer types and stages will be recruited for this study
Patients are actively being treated for another cancer at the time of enrollment
BC patients at Moffitt Cancer Center (MCC)
Has an outpatient appointment within University of North Carolina (UNC) Chapel Hill Lineberger Comprehensive Cancer Center
Be scheduled to start outpatient intravenous (IV) chemotherapy for reasons other than symptom palliation at Moffitt Cancer Center (MCC) or Sylvester Comprehensive Cancer Center (SCCC)
Patients with metastatic cancer or a second primary cancer
Active cancer/metastatic cancer
Meet National Comprehensive Cancer Network (NCCN) criteria for consideration of genetic testing for hereditary breast cancer
Inclusion Criteria: Subjects will be drawn from the pool of all parents who are primary\n        caregivers of children diagnosed with any form of cancer - weeks prior to contact about\n        the Problem Solving Skills Training intervention and cared for at one of the  data\n        collection sites. No attempt will be made to stratify the sample by any particular\n        demographic variables (e.g., age, ethnic background, or type of cancer diagnosed in their\n        child), except that monolingual Spanish-speaking parents will be specifically recruited to\n        provide adequate representation for statistical analysis at Childrens Hospital Los Angeles\n        and UT/MD Anderson Cancer Center. Goal: % total enrollment.\n\n        Exclusion Criteria: Parents of children with cancer will be excluded if () they do not\n        read or speak English or Spanish; () their child is in severe a medical crisis, as\n        determined by the oncologist, or () they live a prohibitive distance to complete the\n        intervention (typically, > miles from the Center) and do not have access to a telephone\n        for phone intervention sessions. Internet access will be facilitated as part of the e-PSST\n        intervention arm. These exclusionary criteria are identical to our previous work; <% of\n        eligible mothers have been excluded.
Coming with the patient at the Seidman Comprehensive Cancer Center at University Hospitals Case Medical Center (UHCMC)
Have volunteered as a student strategist at Comprehensive Cancer Center of Wake Forest University (CCCWFU); all strategists are required to have gone through Take the Fight (TTF) training prior to their volunteer work
Participants will be patients of Vanderbilt-Ingram Cancer Center (VICC) with a diagnosis of cancer
Concurrent participation in Lineberger Comprehensive Cancer Center (LCCC) or LCCC
Subjective concern about declines in cognitive functioning related to a diagnosis of cancer and/or cancer related treatment
Patients who have not undergone any surgical treatment for their cancer
To preserve a homogenous cohort and comply with the departmentally-organized research infrastructure, we will include preoperative abdominal cancer patients undergoing surgery, or healthcare provider from all specialties at MD Anderson Cancer Center (MDACC) or volunteer from MDACC Volunteer Service.
Primary cancer care at the Massachusetts General Hospital (MGH) Cancer Center
Active cancer defined as metastatic disease and/or any evidence of cancer on cross-sectional or positron emission tomography (PET) imaging, cancer related surgery, chemotherapy or radiation therapy within the past  months; note: non-melanoma skin cancer does not meet the cancer requirement
Receiving or planning to receive outpatient therapy for any cancer
Patients who have been surgically treated for breast cancer more than  months; healing usually occurs within  months of surgical treatment for cancer
Oncologists who treat at least  advanced cancer patients per month at a study participating hospital
All the female breast cancer survivors will be at least two months from receiving cancer treatment (surgery, adjuvant therapy or radiation) and within three years from completing cancer treatment, except for tamoxifen/aromatase inhibitors
NON-CANCER PATIENT GROUP: Cancer-free
Treated for any other cancer
Are within traveling distance to Fox Chase Cancer Center (FCCC) and Mount Sinai Medical Center (MSMC)
Patients with lung or esophageal cancer stages I through IIIB who are going to receive at least  weeks of daily thoracic radiation therapy with or without chemotherapy in the department of radiation oncology at M. D. Anderson Cancer Center (MDACC) and have an eligible and consenting family caregiver living with the patient while he/she receives treatment (i.e., adult child, sibling, parent)
No prior history of anal cancer, including SISCCA
Willing to come to MD Anderson Cancer Center (MDACC) or Hospital Israelita Albert Einstein (HIAE) for the meditation sessions and assessment sessions
Receiving cancer care at either Massachusetts General Hospital Cancer Center or community affiliates (North Shore, Emerson, and Massachusetts General Hospital [MGH] West)
History of gynecologic cancer
Cancer (solid tumor) diagnosis or mass suspicious of cancer within past six months as per clinical judgment
Patients with gynecologic cancer who are undergoing vaginal brachytherapy as part of their treatment
Participants with concurrent active cancer or active cancer within the last  years are ineligible unless, at the discretion of the investigator, the patient is deemed to have cancer or cancer treatment that the investigators do not think will interfere with any of the biological measures of the study
No active cancer
Patients must have histologically or cytologically confirmed solid tumor or heme malignancy; exceptions include patients with pancreatic cancer or colon cancer who are receiving oxaliplatin and are thus eligible for Comprehensive Cancer Center of Wake Forest University (CCCWFU) ; patients undergoing inpatient induction therapy for acute leukemia; and those hospitalized for marrow or peripheral blood stem cell transplantation
Diagnosis of gynecological cancer of any type or strong suspicion for cancer
Outpatient at MD Anderson Cancer Center seen by the Supportive Care Service, Thoracic Medical Oncology or Cardiopulmonary Center
Outpatient at MD Anderson Cancer Center seen by the Supportive Care Service or Thoracic Medical Oncology
Outpatients at Monroe Dunaway (MD) Anderson Cancer Center seen by the Supportive Care, Rehabilitation Service, Thoracic Oncology or Pulmonary Medicine
Peer mentors will be past gynecologic cancer patients not currently undergoing treatment for their cancer, and considered without evidence of disease
Inability to perform phone call and clinical follow-up at MD Anderson Cancer Center (MDACC)
Actively undergoing any chemotherapy treatment at Maroone Cancer Center
Patients who have never utilized art therapy at Maroone Cancer Center
Patients not actively undergoing chemotherapy at Maroone Cancer Center
Patients who have previously utilized art therapy at Maroone Cancer Center
Distressing cancer-related recollections that cause physiological reactivity
Patients are undergoing other cancer treatments
Receiving care at University of Michigan Comprehensive Cancer Center Gynecologic Oncology Clinic or at St. Joseph Mercy Hospital, Alexander Cancer Care Center
Participants must be a spouse or domestic partner of a cancer survivor and will be recruited via the Hematopoietic Stem Cell Transplant Database at Fred Hutchinson Cancer Research Center (FHCRC)
No prior history of cancer;
Prior history of cancer (other than skin cancer);
No evidence of cancer (NED)
Previous treatment of any cancer excluding skin cancer
Newly prescribed one of the designated oral cancer medications for treatment of cancer
Patient of one of the participating National Cancer Institute comprehensive cancer centers
Patients receiving chemotherapy for a recurrent gynecologic cancer at the University of Wisconsin-Madison Carbone Cancer Center (UWCCC)
Patients undergoing liver and/or pancreatic surgical resection for malignancy at MD Anderson Cancer Center
Patients who intend to remain under the MD Anderson Cancer Center (MDACC) surgeon's care until completion of the reconstruction
Patients with active nd malignancies other than myelofibrosis, AML, excised skin cancer, early stage cervical and prostate cancer
All patients with mesothelioma or other pathologies undergoing a pleurectomy decortication at MD Anderson Cancer Center
Cancer patients without BRONJ who have been treated with intravenous zoledronate for >=  year duration
Patients will have one of the following diseases: primary hepatocellular cancer, hepatobiliary cancer, or metastatic disease to the liver
Patients with known cancer
History of anal cancer, penile, vulvar, vaginal, or cervical cancer, or signs of any of these malignancies at baseline; participants with prior carcinoma in situ will not be considered to have prior cancer for eligibility purposes
Active cancer defined as metastatic disease and/or any evidence of cancer on cross-sectional or positron emission tomography (PET) imaging, cancer related surgery, chemotherapy or radiation therapy within the past  months; Note: non-melanoma skin cancer does not meet the cancer requirement
Cancer survivor
Currently being actively treated for cancer other than nonmelanoma skin cancer.
Cervical, vulvar, or vaginal lesions suspicious for cancer based on clinical appearance (e.g. necrotic, ulcerated, and/or fungating masses), unless biopsies show no invasive cancer
Patients should receive their definitive treatment at Wake Forest University (WFU) Cancer Center or at Medical University of South Carolina (MUSC) Cancer Center
History of invasive cancer diagnosis =<  months prior to randomization, excepting nonmelanoma skin cancer; patients with Ta adenocarcinoma of the esophagus arising in the setting of Barretts esophagus are eligible for enrollment in the trial
Women currently undergoing cancer treatment or with a known active cancer; history of malignancy is allowed as long as the patient has completed treatment >  months prior to enrollment
Be an intestinal cancer survivor that is a minimum of  months post chemotherapy/radiation treatment; OR be a healthy adult with no prior history of treatment for cancer
Plans to move from Kansas Cancer Center (KC) during the treatment and follow-up phase
History of childhood cancer
>=  years since completion of cancer-directed therapy for first cancer
More than one metastatic cancer active in the last  years
GYNECOLOGIC CANCER: Women with suspected gynecological cancer
Patients with PSMA-positive tumors including prostate cancer, breast cancer, lung cancer, and other tumor types know to express PSMA
Newly diagnosed biopsy proven locoregional invasive breast cancer at MD Anderson Cancer Center, or referred to MD Anderson for treatment after initial radiologic (mammographic, sonographic, etc.) exams at an outside institution in whom NAC is planned
Have been diagnosed with a malignancy/tumor/cancer, including but not limited to: brain tumor, breast cancer, lung cancer, esophageal cancer, lymphoma, or sarcoma
Any patient who will not be returning routinely for follow-up at Massachusetts General Hospital (MGH) or Dana-Farber/ Harvard Cancer Center (DFHCC)
Prior histologic diagnosis of cancer or awaiting biopsy or surgery for cancer evaluation of a mass detected on exam or standard imaging; this includes solid tumors as well as hematologic malignancies
=< % of any given core involved with cancer
Patients who have consented to a therapeutic protocol for the treatment of their cancer
Patient must have no other active cancer at the time of diagnosis of cervical cancer
Patients with head and neck cancer who are scheduled for node dissection surgeries at New York University (NYU) Langone Medical Center or Bellevue hospital, or for a PET/CT at the Cancer Center ( E th St) for treatment planning are eligible
Enrolled at MD Anderson Cancer Center (MDACC), written consent
Patients must already be known to have metastatic, incurable cancer
GROUP : Oncologic patients at MD Anderson Cancer Center (MDACC):
Men with prostate cancer who elect surgery as the primary treatment of their cancer and to be performed at the Moffitt Cancer Center
Be receiving any active pharmaceutical treatments for cancer
A subset of cancer patients being imaged with PET/CT for diagnosis and/or staging of disease at Case Comprehensive Cancer Center
Persons presenting for: physical or dental exams at outside health care centers OR research meetings/gatherings OR subjects identified at MD Anderson Cancer Center (MDACC) who are not already diagnosed with oral cancer or pre oral cancer: this includes patients with malignancies other than oral cancer, and visitors and family members, attendees of the National Health Service (HNS) Oral Cancer Screening event who are willing to participate
History of respiratory tract cancer
Consented for tissue collection on Mays Cancer Center repository - (for Mays Cancer Center patients only)
Physicians (medical oncologists, urologists, and radiation oncologists) who regularly treat patients with prostate cancer at one of the two research sites (Wayne State University/Karmanos Cancer Institute [WSU/KCI] or Hopkins) and who can recruit patients to available trials
Receiving care at the Massachusetts General Hospital (MGH) Cancer Center
AIM : Less than three relevant comorbidities (diabetes, heart disease, stroke and cancer, where cancer counts as  comorbidities for women but  for men)
Patients newly diagnosed with cancer referred from MGH community health centers in Revere, Chelsea, and Charlestown, or surrounding communities referred to receive cancer treatment at the MGH Cancer Center
Admitted to being a current smoker or recent quitter upon admission to MD Anderson Cancer Center (MDACC) (Arm )
Enrolled at  trial sites in: () Washington, District of Columbia (DC) (Lombardi Comprehensive Cancer Center; LCCC), () Boston, Massachusetts (MA) (Dana-Farber Cancer Institute; DFCI), and () New York, New York (NY) (Mount Sinai Medical Center; MSMC)
Exclude any patient who has a history of metastatic cancer
Any health care provider (physician, advanced practice clinician) at a study site (Fox Chase Cancer Center [FCCC] and Fox Chase Cancer Center Partners [FCCCP]) who provides care for NSCLC and/or CRC survivors
Patients who do not undergo routine oncologic care at the chosen Partners site or Fox Chase Cancer Center
Individual adult patient with current or previous known or suspected thyroid cancer or nodule(s) if they come from a family with a high suspicion of hereditary cancer
Off of all cancer therapy for >=  years
FNA results positive for cancer cells
Patients with non-cancer diagnoses, as CALL only provides services for cancer or pre-cancer diagnoses.
